214 related articles for article (PubMed ID: 28594947)
1. Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.
Wang L; Tang C; Xu B; Yang L; Qu L; Li L; Li X; Wang W; Qin H; Gao H; He K; Liu X
PLoS One; 2017; 12(6):e0179000. PubMed ID: 28594947
[TBL] [Abstract][Full Text] [Related]
2. [Detection of Serum Peptides in Patients with Lung Squamous Cell Carcinoma by MALDI-TOF-MS and Analysis of Their Correlation with Chemotherapy Efficacy].
Zhao G; Xu B; Li X; Tang C; Qin H; Wang H; Yang S; Wang W; Gao H; He K; Liu X
Zhongguo Fei Ai Za Zhi; 2017 May; 20(5):318-325. PubMed ID: 28532539
[TBL] [Abstract][Full Text] [Related]
3. Single pemetrexed is noninferior to platinum-based pemetrexed doublet as first-line treatment on elderly Chinese patients with advanced nonsquamous nonsmall cell lung cancer.
Pu X; Li W; Lu B; Wang Z; Yang M; Fan W; Meng L; Lv Z; Xie Y; Wang J
Medicine (Baltimore); 2017 Mar; 96(11):e6002. PubMed ID: 28296721
[TBL] [Abstract][Full Text] [Related]
4. [Association between the ALK Gene Status and the Efficacy of First-line
Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma].
Chen M; Cao H; Ji Y; Mao Y; Shen S; Li X
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):732-736. PubMed ID: 29167001
[TBL] [Abstract][Full Text] [Related]
5. [Association between the HER2 Gene Status and the Efficacy of First-line Pemetrexed Combined with Platinum Chemotherapy in Patients with Advanced Lung
Adenocarcinoma].
Li P; Li B; Shi Y; Zhang F; Shen S; Li X
Zhongguo Fei Ai Za Zhi; 2019 Mar; 22(3):137-142. PubMed ID: 30909992
[TBL] [Abstract][Full Text] [Related]
6. Practice Patterns and Outcomes for Pemetrexed Plus Platinum Doublet as Neoadjuvant Chemotherapy in Adenocarcinomas of Lung: Looking Beyond the Usual Paradigm.
Noronha V; Zanwar S; Joshi A; Patil VM; Mahajan A; Janu A; Agarwal JP; Bhargava P; Kapoor A; Prabhash K
Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):23-29. PubMed ID: 29239731
[TBL] [Abstract][Full Text] [Related]
7. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet.
Xiong Y; Zhao N; Zheng Y; Wang J; Wei F; Ren X
Tumour Biol; 2017 Jun; 39(6):1010428317701639. PubMed ID: 28618954
[TBL] [Abstract][Full Text] [Related]
9. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
[TBL] [Abstract][Full Text] [Related]
10. Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer.
Yang L; Tang C; Xu B; Wang W; Li J; Li X; Qin H; Gao H; He K; Song S; Liu X
PLoS One; 2015; 10(6):e0128970. PubMed ID: 26047516
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Chemotherapeutic Efficacy in Non-Small Cell Lung Cancer by Serum Metabolomic Profiling.
Tian Y; Wang Z; Liu X; Duan J; Feng G; Yin Y; Gu J; Chen Z; Gao S; Bai H; Wan R; Jiang J; Liu J; Zhang C; Wang D; Han J; Zhang X; Cai L; He J; Wang J
Clin Cancer Res; 2018 May; 24(9):2100-2109. PubMed ID: 29437793
[No Abstract] [Full Text] [Related]
12. Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.
Zhou J; Zheng J; Zhang X; Zhao J; Zhu Y; Shen Q; Wang Y; Sun K; Zhang Z; Pan Z; Shen Y; Zhou J
BMC Cancer; 2018 Jan; 18(1):10. PubMed ID: 29298713
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
Zhang YF; Chen ZW; Lu S
Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
15. Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC.
Strimpakos AS; Banerji U; Thavasu P; Tsilimagou A; Psyrri A; Syrigos KN
Oncology; 2015; 89(1):53-9. PubMed ID: 25766505
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].
Zhang RX; Cai DY; Hong TT; Wu XH; Hua D
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):147-51. PubMed ID: 22780936
[TBL] [Abstract][Full Text] [Related]
17. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial.
Han B; Jin B; Chu T; Niu Y; Dong Y; Xu J; Gu A; Zhong H; Wang H; Zhang X; Shi C; Zhang Y; Zhang W; Lou Y; Zhu L; Pei J
Int J Cancer; 2017 Sep; 141(6):1249-1256. PubMed ID: 28560853
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations.
Shi SB; Wang M; Tian J; Li R; Chang CX; Qi JL
Transl Res; 2016 Apr; 170():1-7. PubMed ID: 26687391
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Fan Y; Huang ZY; Yu HF; Luo LH
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
